Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.

Summary

Primary objective:To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension.

Secondary objectives: To evaluate the safety and tolerability of Torsemide-PR.

Conditions

• Hypertension

Interventions

DRUG

Torasemide Prolonged Release (loop diuretic)

DRUG

Torasemide Immediate Release (loop diuretic)

Sponsors & Collaborators

• Ferrer Internacional S.A.

  lead INDUSTRY

Principal Investigators

• Alex Roca, MD, PhD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

• Antonio Coca, MD, PhD · H. Clínic Barcelona, Barcelona, Spain

• Joaquim Vila, MD · Hospital Municipal de Badalona, Badalona, Barcelona, Spain

• Javier Sobrino, MD · Hospital del Esperit Sant, Santa Coloma de Gramanet, Barcelona, Spain

• Jaume Plana, MD · Hospital Residencia Sant Camil, Sant Pere de Ribes, Barcelona, Spain

• Xavier Farres, MD · Centre d'Atenció Primaria El Remei de Vic, Vic, Barcelona, Spain

• Joan Garcia, MD, PhD · Hospital Universitario La Paz

• Manuel Luque, MD · Hospital Clínico San Carlos, Madrid, Spain

• Luis De Teresa, MD · Hospital de Sant Vicenç de Raspeig, Sant Vicenç de Raspeig, Alicante, Spain

• Jose Vicente, MD · Centro de Salud de Petrel, Petrel, Alicante, Spain

• Angela Felip, MD, PhD · Hospital de Mataró, Mataró, Barcelona, Spain

• Pedro Aranda, MD, PhD · Hospital Universitario Carlos Haya, Málaga, Spain

• Pablo Gómez, MD, PhD · Hospital de Jerez de la Frontera, Cádiz, Spain

• Blas Gil, MD · Hospital Clínico Universitario San Cecilio, Granada, Spain

• Joaquín Aracil, MD · Centro de Salud El Cristo, Oviedo, Asturias, Spain

• Miguel A Prieto, MD · Centro de Salud Vallobin Concinos, Oviedo, Asturias, Spain

• Carles Brotons, MD, PhD · Centre d'Atenció Primaria Sardenya, Barcelona, Spain

• Félix Laporta, MD · Centro de Salud La Roda, La Roda, Albacete, Spain

• José A División, MD · Centro de Salud de Fuentealbilla, Fuentealbilla, Albacete, Spain

• Enrique López, MD · Centro de Salud de Chinchilla, Chinchilla, Albacete, Spain

• Carlos Calvo, MD, PhD · Hospital Universitario de Santiago, Santiago de Compostela, Spain

• Emili Marco, MD · Centre d'Atenció Primaria de Sarrià de Ter, Sarrià de Ter, Girona, Spain

• Joan Martorell, MD · Centre de Salut de Guisona, Guisona, Lleida, Spain

• Montserrat Pujol, MD · Centre d'Atenció Primaria El Carmel, Barcelona, Spain

• Raquel Adroer, MD · Centre d'Atenció Primaria Florida Nord, Barcelona, Spain

• Angel Cano, MD · Centre d'Atenció Primaria Bon Pastor, Barcelona, Spain

• Nadezhda S Alexeeva, PhD · St. Petersburg Cardiology Clinic, St. Petesburg, Russia

• Andrei Y Baranovsky, MD, PhD · St. Petersburg City Hospital #31, St. Petesburg, Russia

• Svetlana A Boldueva, MD, PhD · St. Petersburg Mechnikov State Medical Academy, St. Petesburg, Russia

• Svetlana K Churina, MD, PhD · Pokrovskaya Hospital, 1-st and 2-nd Cardiology Department, St. Petesburg, Russia

• Boris M Goloschekin, MD, PhD · St. Petersburg City Hospital #15, St. Petesburg, Russia

• Yanis Y Dumpis, MD · St.Petersburg Mechnikov State Medical Academy North-West Center of Arrhythmia Diagnostics and Treatment, St. Petesburg, Russia

• Konstantin N Zrazhevsky, MD, PhD · St.Petersburg City Hospital #8, St. Petesburg, Russia

• Victor Kostenko, MD, PhD · St.Petersburg City Outpatient Unit #109, St. Petesburg, Russia

• Elena F Pavlysh, MD, PhD · St.Petersburg City Outpatient Unit #25, St. Petesburg, Russia

• Lev A Sorokin, MD, PhD · St. Elizabeth City Hospital, St. Petesburg, Russia

• Irina A Zobenko, MD · JSC Chernaya Rechka Health Center, St. Petesburg, Russia

• Alexander O Sherenkov, MD, PhD · Krasnogvardeysky District Medical-Physiology Clinic, St. Petesburg, Russia

• Alexander V Orlov-Morozov, MD, PhD · Moscow City Hospital #23, Moscow, Russia

• Vladimir A Parfenov, MD, PhD · Moscow City Hospital #61, Moscow, Russia

• Victor A Milyagin, MD, PhD · Smolensk State Medical Academy, Smolensk, Russia

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-04-30

Completion

2006-02-28